Abiopharma

🔍 Schneider Eugene (Executive)

Company: IONIS PHARMACEUTICALS INC (IONS)

Report Date: 2026-06-26

Detailed Transactions and Holdings:

• Acquired 26,000 shares of Common Stock at $60.89 per share (Direct)
  Date: 2026-06-26 | Code: M | equity_swap_involved: 0 | shares_owned_after: 103,114.00 | transaction_form_type: 4
• Sold 26,000 shares of Common Stock at $81.046 per share (Direct)
  Date: 2026-06-26 | Code: S | equity_swap_involved: 0 | shares_owned_after: 77,114.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 26,000 shares of Non-Qualified Stock Option (right to buy) at $60.89 per share (Derivative)
  Date: 2026-06-26 | Code: M | Expires: 2027-01-01 | Exercise: 2021-01-02 | equity_swap_involved: 0 | shares_owned_after: 26,000.00 | transaction_form_type: 4

Footnotes:

• F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.